Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...